40637HAF6 Filings — Halozyme Therapeutics, Inc. - FilingSpy
40637HAF6
Halozyme Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A San Diego biopharma company whose ENHANZE technology uses a naturally occurring enzyme to temporarily loosen the gel-like tissue under the skin, letting large-volume biologic medicines be injected in minutes instead of slowly dripped over hours. Its partners sell drugs built on this platform, such as DARZALEX FASPRO and HYQVIA, and it also makes auto-injector devices and its own products like XYOSTED. Co-founded in 1998 by Dr. Gregory Frost, the company's name blends "hyaluronidase" and "enzyme" — the very molecule its science revolves around.
Royalties rose 50% to $308M on DARZALEX SC and VYVGART Hytrulo uptake, lifting Q2 revenue to $481M.
Royalty crossed $300 million in a single quarter for the first time. Revenue rose 47.7% to $481.0 million and reached $1.90 as DARZALEX SC and VYVGART Hytrulo uptake accelerated and bulk rHuPH20 sales more than doubled. The company authorized a new $1 billion while integrating two acquisitions that are pushing operating expenses higher.
Key takeaways
Royalties rose 50% to $307.7 million, driven by VYVGART Hytrulo up 143% and DARZALEX SC up 27%, while older products Herceptin and MabThera saw price erosion.
Product sales, net rose 59% to $129.6 million, led by a 156% increase in bulk rHuPH20 sales to partners and 19% growth in proprietary XYOSTED sales.
Total operating expenses rose 57% to $193.3 million, with higher cost of sales tied to bulk rHuPH20 volume and increased R&D and SG&A from the Elektrofi and Surf Bio acquisitions.
Section summaries
Management's Discussion and Analysis
Royalties surged 50% to $308M on DARZALEX and VYVGART uptake; $1B buyback authorized amid rising costs from acquisitions.
⌄
Total royalties grew 50% to $307.7M, driven by VYVGART Hytrulo (up 143%) and DARZALEX SC (up 27%), partially offset by price erosion on older products like Herceptin and MabThera.
Product sales, net rose 59% to $129.6M, primarily from a 156% increase in bulk rHuPH20 sales to partners and 19% growth in proprietary XYOSTED sales.
rose 42.1% to $287.7 million and narrowed 2.3 points to 59.8%, as growth outpaced the dollar increase in expenses but not the rate of expense growth.
A new $1.0 billion program was authorized in May 2026, with $332.8 million in shares bought during Q2; cash and equivalents stood at $163.1 million at quarter-end.
The company added new ENHANZE collaborations with GSK and Incyte and a Hypercon deal with Vertex, while Takeda reported positive Phase 2/3 data for TAK-881.
What changed
Q1 2026 flagged royalty against the $240.7 million Q1 base: royalties rose to $307.7 million in Q2, a 27.8% sequential increase, as VYVGART Hytrulo and DARZALEX SC uptake continued to build.
Q1 2026 flagged execution of the $1 billion May 2026 program: the company bought $332.8 million in shares during Q2, putting it on pace to exceed the $400 million minimum expected for the year.
Q1 2026 flagged collaborative beyond the $5.6 million Q1 total: collaborative revenue remained low at $5.6 million in Q2, with no upfront or sales-based milestones recognized, confirming milestone timing rather than a structural decline.
Q1 2026 flagged sequential operating expenses from Elektrofi and litigation: total operating expenses rose to $193.3 million from $192.2 million in Q1, essentially flat sequentially, suggesting the acquisition-related step-up is stabilizing.
What to watch
Q3 2026 royalty against the $307.7 million Q2 base as TECENTRIQ SC, OCREVUS SC, and Opdivo Qvantig contributions build and VYVGART Hytrulo growth continues.
Pace of share repurchases under the $1 billion May 2026 program against $163.1 million in cash and equivalents and $1.94 billion in .
Next ENHANZE or Antares milestone and license payments beyond the $5.6 million Q2 collaborative total, including any from the new GSK and Incyte collaborations.
Outcome of the Merck MDASE patent suit over subcutaneous Keytruda and the EPO DARZALEX SC co-formulation patent appeals.
Total operating expenses increased 57% to $193.3M, with higher cost of sales tied to bulk rHuPH20, and increased R&D and SG&A from the Elektrofi and Surf Bio acquisitions.
A new $1.0B program was authorized in May 2026, with $332.8M in shares bought during Q2; cash and equivalents stood at $231.0M at quarter-end.
The company added new ENHANZE collaborations with GSK and Incyte, and a Hypercon deal with Vertex, while Takeda reported positive Phase 2/3 data for TAK-881.
Quantitative and Qualitative Disclosures About Market Risk
No material change in market risks; Swiss-franc royalty hedges and a conservative investment portfolio limit exposure.
⌄
The company states there have been no material changes in its market risks during the quarter ended June 30, 2026.
Cash equivalents and marketable securities are held in money market funds and U.S. Treasury securities under a policy prioritizing principal preservation.
A hypothetical immediate 10% change in interest rates is not expected to materially impact results of operations based on the current portfolio.
A portion of forecasted Swiss-franc-denominated royalty is hedged using to reduce foreign exchange risk.
Hedge gains and losses are recorded in and reclassified to royalty when the underlying transaction is recognized.
The company does not use derivatives or other financial instruments for speculative trading and sees no significant default or illiquidity risk in its holdings.
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insuran…
⌄
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.
Federal drug-pricing reforms and payer cost-containment pressures could materially reduce revenue from Halozyme's and partners' products.
⌄
An Executive Order and CMS under the IRA create uncertainty around price negotiations, especially for ENHANZE combination therapies.
CMS's June 2026 proposed rule could aggregate certain fixed-combination products with shared active ingredients for price negotiation, potentially expanding exposure.
Third-party payers, including consolidated PBMs and insurers, are demanding higher discounts and rebates, limiting patient access and pressuring net pricing.
State-level drug-pricing legislation and international regulatory issues compound the risk of mandatory price controls and importation.
Complex government price-reporting rules expose the company to fines, penalties, and additional rebates if submitted data is incorrect.